Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of tafasitamab + lenalidomide + R-CHOP versus placebo + R-CHOP in newly diagnosed high-risk DLBCL
MOH_2021-06-09_010009Phase 3Recruiting
- Sponsor
- MorphoSys AG
- Start
- Feb 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) and large-cell lymphoma comparing tafasitamab + lenalidomide + R-CHOP with Control: placebo tafasitamab + placebo lenalidomide + R-CHOP (2 arms). Primary endpoint: Primary efficacy endpoint. Started Feb 2021; status: recruiting.
02
Drugs
tafasitamablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphoma
Beyond the preview
Go deeper on MOH_2021-06-09_010009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-06-09_010009.